Propanolamines

• 

  Subject Areas on Research

  • 125I-labeled p-azidobenzylcarazolol, a photoaffinity label for the beta-adrenergic receptor. Characterization of the ligand and photoaffinity labeling of beta 1- and beta 2-adrenergic receptors. 
  • A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. 
  • A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. 
  • ACP Journal Club. Review: in patients with heart failure, β-blockers reduce mortality but do not differ from each other. 
  • Acquired dynamic left ventricular outflow tract obstruction complicating acute anterior myocardial infarction: serial echocardiographic and clinical evaluation. 
  • Alternative explanation for the apparent "two-step" binding kinetics of high-affinity racemic antagonist radioligands. 
  • Anomalous equilibrium binding properties of high-affinity racemic radioligands. 
  • Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease. 
  • Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. 
  • Betaxolol and timolol. A comparison of efficacy and side effects. 
  • Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. 
  • Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure. 
  • Bucindolol: new hopes from reviewing past data. 
  • Cardiac function and heart failure. 
  • Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Catecholamine-induced desensitization of turkey erythrocyte adenylate cyclase. Structural alterations in the beta-adrenergic receptor revealed by photoaffinity labeling. 
  • Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. 
  • Clinical trials in Japan and the United States. 
  • Combinations of beta-blockers and calcium channel blockers: a cause of malignant perioperative conduction disturbances? 
  • Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. 
  • Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. 
  • Covalent labeling of the beta-adrenergic ligand-binding site with para-(bromoacetamidyl)benzylcarazolol. A highly potent beta-adrenergic affinity label. 
  • Crystallizing thinking about the beta2-adrenergic receptor. 
  • Decrease in myometrial beta-adrenergic receptors with prenatal cocaine use. 
  • Differentiation of hemodynamic, humoral and metabolic responses to beta 1- and beta 2-adrenergic stimulation in man using atenolol and propranolol. 
  • Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes. 
  • Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). 
  • Effect of antidepressant drugs in mice lacking the norepinephrine transporter. 
  • Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. 
  • Effect of timolol on aqueous humor protein concentration in humans. 
  • Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). 
  • Effects of chemical inhibition of N-WASP, a critical regulator of actin polymerization on aqueous humor outflow through the conventional pathway. 
  • Effects of diazoxide and beta adrenergic drugs on spontaneous and induced uterine activity in the pregnant baboon. 
  • Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists. 
  • Endogenous proteinases modulate the function of the beta-adrenergic receptor-adenylate cyclase system. 
  • Endothelial renin-angiotensin pathway. Adrenergic regulation of angiotensin secretion. 
  • Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with unstable angina. 
  • Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003. 
  • Giant vacuoles in the lining endothelium of the human Schlemm's canal after topical timolol maleate. 
  • Gαi is required for carvedilol-induced β1 adrenergic receptor β-arrestin biased signaling. 
  • Heterogeneity in presynaptic regulation of GABA release from hippocampal inhibitory neurons. 
  • High-threshold Ca2+ currents in rat hippocampal interneurones and their selective inhibition by activation of GABA(B) receptors. 
  • Hyperpolarization induces a long-term increase in the spontaneous firing rate of cerebellar Golgi cells. 
  • Identification and sequence of a binding site peptide of the beta 2-adrenergic receptor. 
  • Identification of the subunit structure of rat pineal adrenergic receptors by photoaffinity labeling. 
  • Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. 
  • Impaired expression and functional activity of the beta 3- and beta 1-adrenergic receptors in adipose tissue of congenitally obese (C57BL/6J ob/ob) mice. 
  • In Response. 
  • Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. 
  • Inhibition of premature labor: a multicenter comparison of ritodrine and ethanol. 
  • Inhibition of spontaneous beta 2-adrenergic activation rescues beta 1-adrenergic contractile response in cardiomyocytes overexpressing beta 2-adrenoceptor. 
  • Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. 
  • Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. 
  • Ligand-induced overexpression of a constitutively active beta2-adrenergic receptor: pharmacological creation of a phenotype in transgenic mice. 
  • MARCH2 promotes endocytosis and lysosomal sorting of carvedilol-bound β(2)-adrenergic receptors. 
  • Mammalian beta-adrenergic receptors. Distinct glycoprotein populations containing high mannose or complex type carbohydrate chains. 
  • Mammalian beta-adrenergic receptors. Structural differences in beta 1 and beta 2 subtypes revealed by peptide maps. 
  • Mechanism of intracellular allosteric β2AR antagonist revealed by X-ray crystal structure. 
  • Members of the G protein-coupled receptor kinase family that phosphorylate the beta2-adrenergic receptor facilitate sequestration. 
  • Modeling of sequestration and down regulation in cells containing beta2-adrenergic receptors. 
  • Molecular biology of adrenergic receptors in the rat and frog central nervous system. 
  • Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. 
  • New series of aryloxypropanolamines with both human beta(3)-adrenoceptor agonistic activity and free radical scavenging properties. 
  • Nicardipine is superior to esmolol for the management of postcraniotomy emergence hypertension: a randomized open-label study. 
  • Persistent Catechol-O-methyltransferase-dependent Pain Is Initiated by Peripheral β-Adrenergic Receptors. 
  • Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure. 
  • Phosphorylation of the beta-adrenergic receptor accompanies catecholamine-induced desensitization of turkey erythrocyte adenylate cyclase. 
  • Photoaffinity labeling of beta-adrenergic receptors in mammalian tissues. 
  • Photoaffinity labeling of the beta-adrenergic receptor. 
  • Photoaffinity labeling of turkey erythrocyte beta-adrenergic receptors: degradation of the Mr = 49,000 protein explains apparent heterogeneity. 
  • Photoaffinity labelling of mammalian beta-adrenergic receptors: metal-dependent proteolysis explains apparent heterogeneity. 
  • Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. 
  • Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. 
  • Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. 
  • Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism. 
  • Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction. 
  • Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. 
  • Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study. 
  • Receptor crosstalk: effects of prolonged carbachol exposure on beta 1-adrenoceptors and adenylyl cyclase activity in neonatal rat ventricular myocytes. 
  • Response to cardiac sympathetic activation in transgenic mice overexpressing beta 2-adrenergic receptor. 
  • Sustained stimulation of β2- and β3-adrenergic receptors leads to persistent functional pain and neuroinflammation. 
  • Synthesis of iodine-125 labeled (+/-)-15-(4-azidobenzyl)carazolol: a potent beta-adrenergic photoaffinity probe. 
  • The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications. 
  • The cardiac beta-adrenergic receptor. Structural similarities of beta 1 and beta 2 receptor subtypes demonstrated by photoaffinity labeling. 
  • When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure. 
  • Which beta-blocker for heart failure? 
  • β-Adrenergic receptor antagonists ameliorate myocyte T-tubule remodeling following myocardial infarction. 
  • β-arrestin1-biased β1-adrenergic receptor signaling regulates microRNA processing. 
  • β1-Blockade increases maximal apnea duration in elite breath-hold divers. 
• 

  Keywords of People

  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology